Company intelligence / Profile preview

Templeton

Utrecht, Netherlands

Ownership: Private
Development stage: Other

Overview

Temple Therapeutics is a clinical-stage biotechnology company dedicated to addressing significant unmet needs in women's health and surgical recovery. The company utilizes a proprietary platform focused on cellular metabolism to develop a synergistic pipeline of targeted therapeutics and non-invasive diagnostics. Its lead candidate, TTX333, is being evaluated for the prevention of post-operative tissue fibrosis, a common complication of surgery. Additionally, Temple is advancing programs for endometriosis and ovarian cancer, aiming to provide disease-modifying treatments where current options are limited.

Therapeutic areas: OncologyEndocrinologyImmunologyWomen's Health
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Templeton.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Templeton.

Explore the full profile